The issue of statin safety: where do we stand?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008
   Pooled it
2. Statins, LDL-C and Beyond: A Contemporary Review of Atherosclerotic Cardiovascular Risk Assessment and Management.Journal of lipid and atherosclerosis · 2026
   Review
3. Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells.Acta pharmacologica Sinica · 2022
   Article
4. Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences.European journal of clinical pharmacology · 2016
   Observational
5. A novel therapeutic effect of statins on nephrogenic diabetes insipidus.Journal of cellular and molecular medicine · 2015
   Review
6. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.Pharmacogenomics · 2012
   Review
7. Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer.Open access journal of urology · 2011
   Review
8. Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use.BMJ case reports · 2009
   Article
9. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy.Investigative ophthalmology & visual science · 2008
   Article
10. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?Current atherosclerosis reports · 2008
    Review
11. Clinical efficacy and safety of statins in managing cardiovascular risk.Vascular health and risk management · 2008
    Review
12. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?Drugs & aging · 2008
    Review
13. Cholesterol lowering for secondary prevention: what statin dose should we use?Vascular health and risk management · 2007
    Review
14. Rosuvastatin in elderly patients.Drugs & aging · 2007
    Review
15. Rosuvastatin: an independent analysis of risks and benefits.MedGenMed : Medscape general medicine · 2006
    Review
16. Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly.Drug safety · 2006
    Review
17. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.Drug safety · 2006
    Article

Corrections and comments

• Comment on
  The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.2005

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as